Neoadjuvant Anal Cancer VMAT: Lumbrosacral Plexus Dose Volume Histograms with Standard & Escalated Doses proposed in the ACT5 trial.

Elizabeth Findlay, Thuraiya Al-Hadjri , Lucy Wells, Leslie Samuel

Research output: Contribution to conferencePoster

Abstract

For the majority of patients, the LSP doses observed are well within those reported in the literature available. However the modelling does suggest that for patients with more advanced disease, often with more extensive pelvic nodal disease, who would be allocated higher treatment doses in ACT5, there may be clinical consequences. It would seem prudent to not only contour the LSP in these patients to know the radiation doses their LSP is receiving.
Original languageEnglish
DOIs
Publication statusPublished - 20 Apr 2018
EventEuropean Society for Therapeutic Radiotherapy & Oncology Annual Meeting - Barcelona, Spain
Duration: 20 Apr 201824 Apr 2018
Conference number: 37

Conference

ConferenceEuropean Society for Therapeutic Radiotherapy & Oncology Annual Meeting
Abbreviated titleESTRO 37
CountrySpain
CityBarcelona
Period20/04/1824/04/18

Fingerprint

Anus Neoplasms
Radiation
Therapeutics

Keywords

  • lumbrosacral plexus
  • VMAT; dose volume histograms
  • ACT 5; anal cancer

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Findlay, E., Al-Hadjri , T., Wells, L., & Samuel, L. (2018). Neoadjuvant Anal Cancer VMAT: Lumbrosacral Plexus Dose Volume Histograms with Standard & Escalated Doses proposed in the ACT5 trial.. Poster session presented at European Society for Therapeutic Radiotherapy & Oncology Annual Meeting, Barcelona, Spain. https://doi.org/10.3252/pso.eu.ESTRO37.2018

Neoadjuvant Anal Cancer VMAT: Lumbrosacral Plexus Dose Volume Histograms with Standard & Escalated Doses proposed in the ACT5 trial. / Findlay, Elizabeth; Al-Hadjri , Thuraiya; Wells, Lucy; Samuel, Leslie.

2018. Poster session presented at European Society for Therapeutic Radiotherapy & Oncology Annual Meeting, Barcelona, Spain.

Research output: Contribution to conferencePoster

Findlay, E, Al-Hadjri , T, Wells, L & Samuel, L 2018, 'Neoadjuvant Anal Cancer VMAT: Lumbrosacral Plexus Dose Volume Histograms with Standard & Escalated Doses proposed in the ACT5 trial.' European Society for Therapeutic Radiotherapy & Oncology Annual Meeting, Barcelona, Spain, 20/04/18 - 24/04/18, . https://doi.org/10.3252/pso.eu.ESTRO37.2018
Findlay E, Al-Hadjri T, Wells L, Samuel L. Neoadjuvant Anal Cancer VMAT: Lumbrosacral Plexus Dose Volume Histograms with Standard & Escalated Doses proposed in the ACT5 trial.. 2018. Poster session presented at European Society for Therapeutic Radiotherapy & Oncology Annual Meeting, Barcelona, Spain. https://doi.org/10.3252/pso.eu.ESTRO37.2018
Findlay, Elizabeth ; Al-Hadjri , Thuraiya ; Wells, Lucy ; Samuel, Leslie. / Neoadjuvant Anal Cancer VMAT: Lumbrosacral Plexus Dose Volume Histograms with Standard & Escalated Doses proposed in the ACT5 trial. Poster session presented at European Society for Therapeutic Radiotherapy & Oncology Annual Meeting, Barcelona, Spain.
@conference{4a1e2cc0da96452cb855a4b0ba63eb96,
title = "Neoadjuvant Anal Cancer VMAT: Lumbrosacral Plexus Dose Volume Histograms with Standard & Escalated Doses proposed in the ACT5 trial.",
abstract = "For the majority of patients, the LSP doses observed are well within those reported in the literature available. However the modelling does suggest that for patients with more advanced disease, often with more extensive pelvic nodal disease, who would be allocated higher treatment doses in ACT5, there may be clinical consequences. It would seem prudent to not only contour the LSP in these patients to know the radiation doses their LSP is receiving.",
keywords = "lumbrosacral plexus, VMAT; dose volume histograms, ACT 5; anal cancer",
author = "Elizabeth Findlay and Thuraiya Al-Hadjri and Lucy Wells and Leslie Samuel",
year = "2018",
month = "4",
day = "20",
doi = "10.3252/pso.eu.ESTRO37.2018",
language = "English",
note = "European Society for Therapeutic Radiotherapy & Oncology Annual Meeting, ESTRO 37 ; Conference date: 20-04-2018 Through 24-04-2018",

}

TY - CONF

T1 - Neoadjuvant Anal Cancer VMAT: Lumbrosacral Plexus Dose Volume Histograms with Standard & Escalated Doses proposed in the ACT5 trial.

AU - Findlay, Elizabeth

AU - Al-Hadjri , Thuraiya

AU - Wells, Lucy

AU - Samuel, Leslie

PY - 2018/4/20

Y1 - 2018/4/20

N2 - For the majority of patients, the LSP doses observed are well within those reported in the literature available. However the modelling does suggest that for patients with more advanced disease, often with more extensive pelvic nodal disease, who would be allocated higher treatment doses in ACT5, there may be clinical consequences. It would seem prudent to not only contour the LSP in these patients to know the radiation doses their LSP is receiving.

AB - For the majority of patients, the LSP doses observed are well within those reported in the literature available. However the modelling does suggest that for patients with more advanced disease, often with more extensive pelvic nodal disease, who would be allocated higher treatment doses in ACT5, there may be clinical consequences. It would seem prudent to not only contour the LSP in these patients to know the radiation doses their LSP is receiving.

KW - lumbrosacral plexus

KW - VMAT; dose volume histograms

KW - ACT 5; anal cancer

U2 - 10.3252/pso.eu.ESTRO37.2018

DO - 10.3252/pso.eu.ESTRO37.2018

M3 - Poster

ER -